* Lilly's pill clearance secures early edge over Novo Nordisk in world's second-largest drug market * China still to approve Novo's oral Wegovy * Analysts expect it to ultimately outpace Lilly's pill
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)